BMS
This article was originally published in The Rose Sheet
Executive Summary
As President and CEO Peter Dolan takes helm May 1, one of his initial charges will be divesting Clairol as part of strategy to fund biologic products acquisitions. Bristol-Myers Squibb is rumored to have received bids from Procter & Gamble and Kao (1see story, p. 6). Exec also is expected to focus on building Bristol's international business, particularly in Europe and Japan. Dolan, who was appointed president and member of the board in January 2000, succeeds retired Chairman Charles Heimbold. Acquisition growth strategy and Clairol divestiture were announced by Bristol in September (2"The Rose Sheet" Oct. 2, 2000, p. 3)
|
As President and CEO Peter Dolan takes helm May 1, one of his initial charges will be divesting Clairol as part of strategy to fund biologic products acquisitions. Bristol-Myers Squibb is rumored to have received bids from Procter & Gamble and Kao (1 (Also see "P&G, Kao Square Off In Bid For Bristol's Clairol" - HBW Insight, 7 May, 2001.)). Exec also is expected to focus on building Bristol's international business, particularly in Europe and Japan. Dolan, who was appointed president and member of the board in January 2000, succeeds retired Chairman Charles Heimbold. Acquisition growth strategy and Clairol divestiture were announced by Bristol in September (2 (Also see "Clairol/Pharma Business Exchange Sought By Bristol-Myers" - HBW Insight, 2 Oct, 2000.)). |